Mirati Therapeutics, Inc. Blog | Talkmarkets

Latest Posts

Check Your Portfolio For Small Cap Weighting: Growth, Innovation Or Speculation?

Article By: Rod Raynovich

Monday, August 15, 2022 5:12 AM EDT

The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring biotech small cap performance.

In this article: CYRX, QDEL, IWM, XBI, CCXI, EVH, ARKG, MRTX

Read

Piper Says Mirati Now 'Prime' Biotech Takeout Candidate, Boosts Target

Article By: The Fly

Thursday, November 5, 2020 5:37 AM EDT

Piper Sandler analyst Tyler Van Buren raised the firm's price target on Mirati Therapeutics to $260 from $210 and keeps an Overweight rating on the shares.

In this article: MRTX

Read

Mirati Therapeutics - All Time High

Article By: Jim Van Meerten

Thursday, October 29, 2020 2:14 PM EDT

Revenue expected to grow 566.90% next year.

In this article: MRTX

Read

Biotech Stocks Emerge Unscathed And Ready To Go

Article By: Tarun Chandra, CFA

Friday, May 18, 2018 8:41 PM EDT

The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.

In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX

Read